An outbreak of multi-drug resistant Escherichia coli urinary tract infection in an elderly population: A case-control study of risk factors

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Ikram, Rosemary ^a   Psutka, Rebecca ^b   Carter, Alison ^a   Priest, Patricia ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antimicrobial prescribing; Bacterial; Drug resistance; Escherichia coli; Hospital; Nursing home; Risk factors; UTI

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; MACROLIDE; NITROFURANTOIN; NORFLOXACIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; ANTIINFECTIVE AGENT; BACTERIAL DNA;

AGED; ARTICLE; BACTERIAL TRANSLOCATION; BACTERIUM ISOLATION; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ELDERLY CARE; EPIDEMIC; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; FRAIL ELDERLY; HOSPITAL PATIENT; HUMAN; INDEPENDENCE; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; NONHUMAN; NURSING HOME; PRESCRIPTION; RISK ASSESSMENT; SEX DIFFERENCE; URINALYSIS; URINARY TRACT INFECTION; AGE; COMPLICATION; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENETICS; ISOLATION AND PURIFICATION; MULTIDRUG RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; ODDS RATIO; PATHOLOGY; PULSED FIELD GEL ELECTROPHORESIS; RECURRENT DISEASE; RISK FACTOR; URINARY TRACT INFECTIONS; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE OUTBREAKS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; NURSING HOMES; ODDS RATIO; RECURRENCE; RISK FACTORS; SEX FACTORS; URINARY TRACT INFECTIONS;

EID: 84938955789     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0974-0     Document Type: Article

References (28)

1. Yoshikawa TT. Perspective: aging and infectious diseases: past, present, and future. J Infect Dis. 1997;176(4):1053-7.
2. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001;183(Supplement 1):S1-4.
3. Richards CL. Urinary tract infections in the frail elderly: issues for diagnosis, treatment and prevention. Int Urol Nephrol. 2004;36(3):457-63.
4. Karlowsky JA, Jones ME, Thornsberry C, Critchley I, Kelly LJ, Sahm DF. Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999. Int J Antimicrob Agents. 2001;18(2):121-7.
5. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA. 1999;281(6):517-23.
6. Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis. 2006;42(7):925-34.
7. Nicolle LE, Long-Term-Care-Committee S. Urinary tract infections in long-term-care facilities. Infect Control Hosp Epidemiol. 2001;22(3):167-75.
8. Laupland K, Ross T, Pitout JDD, Church D, Gregson D. Community-onset urinary tract infections: a population-based assessment. Infection. 2007;35(3):150-3.
9. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect. 2007;55(3):254-9.
10. Cooke NM, Smith SG, Kelleher M, Rogers TR. Major differences exist in frequencies of virulence factors and multidrug resistance between community and nosocomial Escherichia coli bloodstream isolates. J Clin Microbiol. 2010;48(4):1099-104.
11. Horcajada JP, Shaw E, Padilla B, Pintado V, Calbo E, Benito N, et al. Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clin Microbiol Infect. 2013;19(10):962-8.
12. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23(3):163-7.
13. Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004;42(3):1089.
14. Eom JS, Hwang BY, Sohn JW, Kim WJ, Kim MJ, Park SC, et al. Clinical and molecular epidemiology of quinolone-resistant Escherichia coli isolated from urinary tract infection. Microb Drug Resist. 2002;8(3):227-34.
15. Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection. 2008;36(1):41-5.
16. Wu UI, Yang CS, Chen WC, Chen YC, Chang SC. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. J Microbiol Immunol Infect. 2010;43(4):310-6.
17. Hillier S, Roberts Z, Dunstan F, Butler C, Howard A, Palmer S. Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study. J Antimicrob Chemother. 2007;60(1):92-9.
18. Kuster SP, Hasse B, Huebner V, Bansal V, Zbinden R, Ruef C, et al. Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection. 2010;38(1):33-40.
19. Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. J Antimicrob Chemother. 2001;47(6):781-7.
20. Goering R. Pulsed-field electrophoresis. In: Persing DH, Tenover FC, Versalovic J, Tang YW, Unger ER, Relman DA, White TJ, editors. Molecular microbiology: diagnostic principles and practice. Washington: ASM Press; 2004. p. 185-96.
21. Foxman B, Zhang L, Koopman JS, Manning SD, Marrs CF. Choosing an appropriate bacterial typing technique for epidemiologic studies. Epidemiol Perspect Innov. 2005;2:10.
22. StataCorp. Stata statistical software. In: Release. 12th ed. College Station: StataCorp LP; 2011.
23. Kuenzli E, Jaeger VK, Frei R, Neumayr A, DeCrom S, Haller S, et al. High colonization rates of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in Swiss travellers to South Asia- a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors. BMC Infect Dis. 2014;14:528.
24. Rogers BA, Doi Y. Who is leading this dance? Understanding the spread of Escherichia coli sequence type 131. Infect Control Hosp Epidemiol. 2013;34(4):370-2.
25. Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol. 2013;34(4):361-9.
26. Galvin S, Bergin N, Hennessy R, Hanahoe B, Murphy AW, Cormican M, et al. Exploratory spatial mapping of the occurrence of antimicrobial resistance in E.coli in the community. Antibiotics. 2013;2:328-38.
27. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis. 2002;34(12):1558-63.
28. The Healthcare Infection Control Advisory Committee, Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multi-drug resistant organisms in healthcare settings. Atlanta: CDC; 2006.